CEO: Naseem Amin

Advent Contact: Alain Huriez

Best-in-class treatment for Wilson's disease

Orphalan was incorporated in 2011 to reposition drugs in orphan diseases by exploiting untapped academic research and existing clinical data. The lead indication is Wilson’s disease which results from the toxic accumulation of copper in the body. Current treatments are not satisfactory due to harmful side effects or complex drug handling requirements. Orphalan has developed a best in class molecule to address this unmet medical need.

Advent was the sole institutional investor in the Series A in 2015.